An 82-year-old woman with a fragility fracture of the hip is assessed post-operatively. She has a T-score of –3.0 on DEXA scanning and no contraindications to treatment. According to UK guidance, what is the most appropriate first-line pharmacological treatment for secondary prevention of osteoporotic fractures?